Emerging therapies for migraine

被引:41
作者
Goadsby, Peter J.
机构
[1] UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, London WC1N 3BG, England
[2] Great Ormond St Hosp Sick Children, London WC1N 3JH, England
来源
NATURE CLINICAL PRACTICE NEUROLOGY | 2007年 / 3卷 / 11期
关键词
acute-attack treatments; clinical trials; migraine; neural mechanisms; prevention;
D O I
10.1038/ncpneuro0639
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Migraine is a common disabling brain disorder that-considering its clinical and economic impact-is understudied and in need of additional management options. Currently, treatments are classified as preventive or acute-attack therapies, although it is expected that this distinction will become blurred over time. The gap-junction blocker tonabersat, an inducible nitric oxide synthase (NOS) inhibitor and botulinum toxin A are all being investigated in clinical trials as preventive therapies. Device-based approaches using neurostimulation of the occipital nerve have provided promising results, whereas the first study of patent foramen ovale closure for migraine prevention produced disappointing results. Calcitonin gene-related peptide receptor antagonists, vanilloid TRPV1 receptor antagonists and NOS inhibitors are all being investigated in clinical trials for acute migraine. There is much cause for optimism in this area of neurology and considerable benefit awaits our patients.
引用
收藏
页码:610 / 619
页数:10
相关论文
共 137 条
[1]   Neuroimaging of migraine [J].
Afridi S.K. ;
Goadsby P.J. .
Current Pain and Headache Reports, 2006, 10 (3) :221-224
[2]   Glyceryl trinitrate triggers premonitory symptoms in migraineurs [J].
Afridi, SK ;
Kaube, H ;
Goadsby, PJ .
PAIN, 2004, 110 (03) :675-680
[3]   Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation [J].
Akerman, S ;
Kaube, H ;
Goadsby, PJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (04) :718-724
[4]   GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo [J].
Alderton, WK ;
Angell, ADR ;
Craig, C ;
Dawson, J ;
Garvey, E ;
Moncada, S ;
Monkhouse, J ;
Rees, D ;
Russell, LJ ;
Russell, RJ ;
Schwartz, S ;
Waslidge, N ;
Knowles, RG .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 145 (03) :301-312
[5]   Cost of disorders of the brain in Europe [J].
Andlin-Sobocki, P ;
Jönsson, B ;
Wittchen, HU ;
Olesen, J .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 :1-+
[6]   Potential source of cerebral embolism in migraine with aura - A transcranial Doppler study [J].
Anzola, GP ;
Magoni, M ;
Guindani, M ;
Rozzini, L ;
Dalla Volta, G .
NEUROLOGY, 1999, 52 (08) :1622-1625
[7]   Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A [J].
Aoki, KR .
NEUROTOXICOLOGY, 2005, 26 (05) :785-793
[8]   Suppression of cortical spreading depression in migraine prophylaxis [J].
Ayata, C ;
Jin, HW ;
Kudo, C ;
Dalkara, T ;
Moskowitz, MA .
ANNALS OF NEUROLOGY, 2006, 59 (04) :652-661
[9]   Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons [J].
Bellamy, J ;
Bowen, EJ ;
Russo, AF ;
Durham, PL .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (08) :2057-2066
[10]   Animal models of migraine: looking at the component parts of a complex disorder [J].
Bergerot, A. ;
Holland, P. R. ;
Akerman, S. ;
Bartsch, T. ;
Ahn, A. H. ;
MaassenVanDenBrink, A. ;
Reuter, U. ;
Tassorelli, C. ;
Schoenen, J. ;
Mitsikostas, D. D. ;
van den Maagdenberg, A. M. J. M. ;
Goadsby, P. J. .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 24 (06) :1517-1534